
    
      The study was performed in 2 staggered phases, Phase A and Phase B. In Phase A, participants
      were randomized to qHPV, Octavalent HPV with 15 mcg IMX/AAHS, or Octavalent HPV with 30 mcg
      IMX/AAHS. After the safety for Phase A was reviewed, Phase B was initiated. In Phase B,
      participants were randomized to qHPV, Octavalent HPV with 60 mcg IMX/AAHS or Octavalent HPV
      with 120 mcg IMX/AAHS.
    
  